NCT00088543: Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant |
|
|
| Completed | N/A | 60 | US, Canada | Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] | Genzyme, a Sanofi Company | Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD) | 04/06 | 04/06 | | |
NCT01499147: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies |
|
|
| Completed | N/A | 100 | US | fludarabine/busulfan, Fludarabine:, Fludarabine Phosphate, Fludara, Busulfan:, Busulfex, Myleran, fludarabine/ melphalan, Fludarabine phosphate, Melphalan:, Alkeran, ATG, Thymoglobulin | University of Illinois at Chicago | Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Multiple Myeloma, Lymphocytic Leukemia, Myeloproliferative Disorder, Polycythemia Vera, Myelofibrosis, Aplastic Anemia | 05/13 | 05/13 | | |